Lytix Biopharma AS: Annual Report for 2023

Oslo, Norway, April 30, 2024 – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that it has published its Annual Report for 2023, which was approved by the board of directors on April 29, 2024.

“In 2023, our unique position in the immune-oncology field has been strengthened with positive interim results from two phase II studies. Our oncolytic molecules have the potential to solve one of the major challenges in current cancer therapy: tumor heterogeneity”, says Øystein Rekdal, CEO of Lytix Biopharma.

The Annual Report for 2023 is attached to this notice and is also available on the company’s website, www.lytixbiopharma.com, under Investors.

For further information, please see the Company’s website or contact CFO Gjest Breistein. Please see below for contact details.

Gjest Breistein, CFO

E-mail: gjest.breistein@lytixbiopharma.com

Phone: +47 952 60 512

About Lytix

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.